title: Juvenile psoriatic arthritis and acquired sensorineural hearing loss in a teenager: is there an association?
abstract: Autoimmune inner ear disease is a cause of sensorineural hearing loss, first described in 1979 by McCabe. The occurrence during rheumatic diseases is already documented in adults, but to our knowledge, this evidence is still lacking in children. A 13-yr-old girl affected by juvenile psoriatic arthritis, treated with etanercept, developed a bilateral and asymmetric sensorineural deafness. The patient significantly improved after steroid administration. Once ruled out the principal causes of sensorineural hearing loss, we also considered the hypothesis of an anti-TNF side effect. However, the clinical presentation, the efficacy on steroid treatment and the presence of inner ear auto-antibodies prompt us to consider autoimmune-SNHL as the most plausible diagnosis. The young age of our patient seems to suggest a genetic susceptibility to autoimmunity and supports the concept of associated autoimmune diseases.
authors.affiliation: Department of Paediatrics, Rheumatology Unit, University of Florence, Florence, Italy.
authors.forename: T
authors.initials: T
authors.lastname: Giani
authors.forename: G
authors.initials: G
authors.lastname: Simonini
authors.forename: C
authors.initials: C
authors.lastname: Lunardi
authors.forename: A
authors.initials: A
authors.lastname: Puccetti
authors.forename: M
authors.initials: M
authors.lastname: De Martino
authors.forename: F
authors.initials: F
authors.lastname: Falcini
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D020274:Autoimmune Diseases of the Nervous System / Q000209:etiology / Q000276:immunology / Q000473:pathology; D002648:Child; D000068800:Etanercept; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D011241:Prednisone; D008775:Methylprednisolone